This documentary video accompanies the scientific article, "Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases" that published in CNS Drugs by the Institute for Neurological Research, a private medical group in Los Angeles.
If the video doesn’t play, it is accessible via this link: www.vimeo.com/18550399.
Los Angeles — A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has been published In the February 1 issue of the journal CNS Drugs, the first human results of a new method of targeting chronic brain inflammation years after stroke are reported. Rapid improvement in impaired motor function, gait, hand function, sensory deficits, spatial perception, speech, cognition and behavior were noted among the first three consecutive patients treated. All patients reportedly demonstrated improvement beginning within 10 minutes of drug administration.
The study, conducted by Edward Tobinick MD, director of the Institute for Neurological Research in Los Angeles, and an assistant clinical professor of Medicine at the David Geffen School of Medicine at UCLA, utilized a new method of delivery of Etanercept, a potent biotechnology anti-inflammatory therapeutic. Etanercept has been a breakthrough for rheumatoid arthritis and other inflammatory disorders. It works by neutralizing tumor necrosis factor (TNF), a cytokine that initiates and amplifies inflammation. The therapeutic potential of etanercept in Alzheimer’s disease, traumatic brain injury, spinal cord injury, sciatica, and other neuroinflammatory disorders has attracted increasing attention.
Previous research had produced evidence of chronic brain inflammation following stroke. The CNS Drugs results provide, for the first time, proof-of-concept that targeting chronic brain inflammation is a viable therapeutic approach in humans years after stroke. The medical need is massive; in the United States alone approximately 795,000 individuals suffer a new or recurrent stroke each year. This calculates to a stroke happening every 40 seconds. At present, these patients lack treatment options to reverse the chronic disability that often results and many require full time care.
These new results provide a new direction for stroke research. In their most recent consensus statement, “Stroke: Working Towards a Prioritized World Agenda," leading stroke researchers recognized the need to “scan the scientific landscape to embrace new ideas and approaches …[and] think outside the box … could advances in the understanding of … inflammation dramatically change our thinking about stroke pathogenesis?”
“The possibility of a leap in our understanding of brain dysfunction caused by stroke by exploring inflammatory pathways was anticipated by the forward-thinking stroke research community,” said Dr Tobinick, the inventor of the etanercept delivery method. “There is potential to address enormous unmet medical need."
SOURCE: Institute For Neurological Research